Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Dowpharma Signs Drug Technology Deals
March 5, 2007
| A version of this story appeared in
Volume 85, Issue 10
Merck and Serum Institute of India have separately licensed Dowpharma's Pfenex technology, a Pseudomonas fluorescens-based fermentation method for making proteins. Dowpharma has developed a high-yielding strain that Merck will use to produce a protein vaccine component. The agreement with Merck also covers other proteins for use in human medicines. Meanwhile, Serum Institute will use the technology to produce an unspecified protein for its vaccine products.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X